Drug Deal Disclosure Act
- Sponsor
- Sen. Wyden, Ron [D-OR]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Apr 21, 2026
Bottom line
The Drug Deal Disclosure Act aims to increase transparency around private drug pricing deals between the federal government and pharmaceutical manufacturers by requiring public disclosure and independent analysis of their economic impacts.
What it actually does
This bill mandates the Department of Health and Human Services (HHS) to publicly release all records and communications related to drug pricing agreements between federal entities and drug manufacturers entered into on or after January 20, 2025. These agreements include those with most-favored-nation clauses, direct-to-consumer sales, import exemptions, or special treatment in federal programs. It also requires the Congressional Budget Office (CBO) and Government Accountability Office (GAO) to jointly analyze the economic and budgetary effects of these disclosed agreements.
Proponents argue
Proponents argue that this bill is crucial for transparency and accountability in drug pricing, allowing the public and Congress to understand the true nature and impact of federal drug deals. They believe it will shed light on potentially hidden costs, inform policy decisions, and ultimately help lower drug prices for consumers by exposing opaque practices.
Opponents contend
Opponents might contend that forcing the disclosure of sensitive commercial agreements could undermine future negotiations, making manufacturers less willing to offer favorable terms if their proprietary information becomes public. This could potentially lead to fewer or less beneficial deals, or even higher drug prices, and may be seen as an overreach into private sector contracts.
The bill is concise and its core provisions are easily understandable, allowing for a quick assessment of its intent and primary mechanisms.
Section 2(a)(1)
Mandated Public Disclosure of Drug Pricing Agreements
This provision requires the Secretary of Health and Human Services to publicly release, within 30 days of enactment, all records, communications, and agreements related to drug pricing deals between federal entities and drug manufacturers since January 20, 2025. This includes agreements involving reduced prices referencing foreign nations, direct-to-consumer sales, import duty exemptions, U.S. investment commitments, special treatment in Medicare/Medicaid innovation models (like GLOBE or GUARD), contributions to the Strategic National Stockpile, or Commissioner's National Priority Review Vouchers.
Supporters argue
Supporters argue this provision is crucial for transparency, allowing the public and Congress to understand how drug pricing deals are made and their true impact on costs. It promotes accountability for federal agencies and manufacturers, potentially leading to more favorable terms for consumers.
Critics contend
Opponents might argue that forcing disclosure of sensitive commercial agreements could undermine future negotiations, as manufacturers may be less willing to offer favorable terms if they know the details will become public, potentially leading to fewer or less beneficial deals.
Tradeoffs
Balances the public's right to know and government accountability against the potential for chilling future private negotiations and the protection of proprietary business information.
Section 2(a)(2)
Enumeration of Specific Agreements for Immediate Disclosure
This section explicitly lists 16 major pharmaceutical companies, including AbbVie, Amgen, Pfizer, and Johnson & Johnson, along with the dates their agreements were publicly announced. It mandates that information related to these specific deals, which are already known to exist, be among the first released by the Secretary, ensuring immediate focus on these high-profile agreements.
Section 2(b) and 2(c)
Rules for Withholding or Redacting Information
The bill explicitly prohibits withholding or redacting information based on reputational harm or political sensitivity. However, it permits redactions for proprietary pricing information, data legally prohibited from disclosure by foreign law or court order, or other applicable law. Any such redaction requires a written justification to be published in the Federal Register and submitted to Congress. Additionally, the Secretary must disclose whether they were provided access to confidential pricing information by each manufacturer.
Section 3
Congressional Oversight Report on Disclosures
Within 15 days of completing the initial release of agreements, the Secretary is required to submit a comprehensive report to key congressional committees, including the Senate Finance and HELP Committees and House Energy & Commerce, Education & Workforce, and Ways & Means Committees. This report must detail all documents and information released, as well as any withheld information, including a summary of redactions and their legal justifications.
Section 4
Independent Economic and Budgetary Analysis of Disclosed Agreements
Within 90 days of the initial disclosure, the Congressional Budget Office (CBO) and Government Accountability Office (GAO) are jointly required to publish a report. This report will analyze the economic and budgetary effects of all disclosed agreements, including direct cost savings for individuals (by insurance status), impacts on Medicare, Medicaid, and qualified health plans, and effects on drug price competition, the Federal Anti-Kickback Statute, and health plan formulary design.
Requires the Secretary to disclose whether they were provided access to confidential pricing information by each individual manufacturer, even if that information is ultimately redacted from public release.
Section 2(c)(1)
Why it matters:This is standard legislative practice for adding a layer of accountability to exceptions. It's not necessarily evasive but requires careful reading to fully grasp its implications for assessing the completeness of disclosures.
Case for: Supporters would argue this ensures a higher level of transparency, allowing the public and Congress to understand if the Secretary had full information when making redaction decisions, even if the pricing itself remains confidential. It prevents the Secretary from simply claiming 'proprietary information' without indicating whether they actually saw it.
Case against: No strong case against this specific transparency measure is typically raised. Manufacturers might prefer less disclosure overall, but this specific point is about the Secretary's access, not the pricing itself, making it hard to oppose on commercial grounds.
Estimated impact: Moderate impact on accountability and public trust in the disclosure process. It doesn't directly impact drug prices but affects the perception of transparency and the integrity of the information release.